ResMed Inc.

NYSE:RMD 주식 보고서

시가총액: US$28.1b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ResMed 미래 성장

Future 기준 확인 2/6

ResMed (는) 각각 연간 13.5% 및 7.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 12.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 22.2% 로 예상됩니다.

주요 정보

13.5%

수익 성장률

12.8%

EPS 성장률

Medical Equipment 수익 성장16.6%
매출 성장률7.0%
향후 자기자본 수익률22.2%
애널리스트 커버리지

Good

마지막 업데이트28 Jun 2024

최근 미래 성장 업데이트

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recent updates

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10
Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06
Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01
Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07
ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30
ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02
A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Apr 24
ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

Apr 09
Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Mar 26
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

ResMed goes ex dividend tomorrow

Feb 07

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Feb 06
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

ResMed: The GARP Story Continues, Technicals Showing Vital Signs

Jan 26

Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

Jan 23
Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease

Dec 28
We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease

Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)

Dec 16
Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)

ResMed: Strong Earnings Growth Supports The High Valuation, Unclear Technical Trends

Nov 14

수익 및 매출 성장 예측

NYSE:RMD - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
6/30/20265,3531,3781,4161,52219
6/30/20255,0361,2401,2821,39122
6/30/20244,6771,0241,1541,26122
3/31/20244,5849581,0711,199N/A
12/31/20234,5048909441,079N/A
9/30/20234,375907792935N/A
6/30/20234,223898559693N/A
3/31/20234,016863408535N/A
12/31/20223,763809222370N/A
9/30/20223,624786305461N/A
6/30/20223,578779195351N/A
3/31/20223,539779344498N/A
12/31/20213,444522446577N/A
9/30/20213,349500397527N/A
6/30/20213,197475620737N/A
3/31/20213,091457733840N/A
12/31/20203,092699774884N/A
9/30/20203,028680684784N/A
6/30/20202,957622696802N/A
3/31/20202,892513505614N/A
12/31/20192,784455420514N/A
9/30/20192,699419487573N/A
6/30/20192,607405382459N/A
3/31/20192,525446374447N/A
12/31/20182,455450385456N/A
9/30/20182,405335390459N/A
6/30/20182,340316434505N/A
3/31/20182,273307444516N/A
12/31/20172,196285N/A434N/A
9/30/20172,125352N/A422N/A
6/30/20172,067342N/A414N/A
3/31/20172,029324N/A417N/A
12/31/20161,968327N/A474N/A
9/30/20161,893346N/A510N/A
6/30/20161,839352N/A548N/A
3/31/20161,773357N/A505N/A
12/31/20151,742357N/A471N/A
9/30/20151,710353N/A421N/A
6/30/20151,679353N/A383N/A
3/31/20151,641353N/A399N/A
12/31/20141,616352N/A409N/A
9/30/20141,578348N/A387N/A
6/30/20141,555345N/A391N/A
3/31/20141,554331N/A400N/A
12/31/20131,540325N/A406N/A
9/30/20131,532317N/A415N/A
6/30/20131,514307N/A403N/A

애널리스트 미래 성장 예측

수입 대 저축률: RMD 의 연간 예상 수익 증가율( 13.5% )이 saving rate( 2.4% 보다 높습니다. ).

수익 vs 시장: RMD 의 연간 수익( 13.5% ) US 시장( 14.9% 보다 느리게 성장할 것으로 예상됩니다. 14.9% 연간).

고성장 수익: RMD 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: RMD 의 수익(연간 7.1% ) US 시장( 8.7% 보다 느리게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: RMD 의 수익(연간 7.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: RMD 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 22.2 %)


성장 기업 발견